Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

69.90EUR
19 Feb 2018
Change (% chg)

€-1.40 (-1.96%)
Prev Close
€71.30
Open
€71.80
Day's High
€71.80
Day's Low
€69.75
Volume
97,296
Avg. Vol
79,010
52-wk High
€82.10
52-wk Low
€56.90

Select another date:

Tue, Jan 30 2018

BRIEF-DiaSorin Sees Tax Benefit In 2015-2017 Of 16-18 Mln Euros From Patent Box

* SIGNS AGREEMENT WITH TAX OFFICE REGARDING PATENT BOX TAX REGIME

BRIEF-Qiagen, DiaSorin partner in automated tuberculosis detection

* SAYS ‍QIAGEN AND DIASORIN PARTNER TO OFFER FULLY AUTOMATED TUBERCULOSIS DETECTION WITH QUANTIFERON-TB GOLD PLUS AVAILABLE ON LIAISON ANALYZER SYSTEMS​

BRIEF-Diasorin And Qiagen Partner To Offer Fully Automated Solution For Diagnosis Of Tuberculosis

* ANNOUNCES PARTNERSHIP WITH QIAGEN TO OFFER FULLY AUTOMATED SOLUTION FOR DIAGNOSIS OF TUBERCULOSIS

BRIEF-Diasorin Receives CE Mark For A New Bordetella Molecular Diagnostic Test

* RECEIVES CE MARK FOR A NEW BORDETELLA MOLECULAR DIAGNOSTIC TEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO

BRIEF-Diasorin revises its FY 2019 guidance

* INCREASES ITS 2019 REVENUE GUIDANCE TO ABOUT EUR 775 MILLION FROM EUR 735 MILLION

BRIEF-DiaSorin ‍completes acquisition of Elisa immunodiagnostic business portfolio​

* ‍COMPLETES ACQUISITION OF ELISA IMMUNODIAGNOSTIC BUSINESS PORTFOLIO AND ASSOCIATED ASSETS FROM SIEMENS HEALTHINEERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DiaSorin ‍earns CE-mark extending sample claims for its Simplexa HSV 1&2 kit​

* ‍EARNS CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR'S SIMPLEXA HSV 1 & 2 KIT​

Select another date: